Trofinetide Side Effects: Safety Signals and Warnings
Trofinetide safety concerns are compound-specific. The main listed side effects are Diarrhea (~80% of patients), Weight loss, and Vomiting. The main warning signals are Monitor weight and nutritional status closely - weight loss is common, Diarrhea may require dose interruption or reduction, and Hepatic monitoring recommended during treatment.
Direct Answer
Trofinetide (Daybue) is FDA-approved as the first treatment specifically indicated for Rett syndrome - a significant regulatory milestone for a devastating neurodevelopmental disorder. Phase 3 data from the LAVENDER trial showed statistically significant improvement on the Rett Syndrome Behaviour Questionnaire and clinician global impression scores. A landmark approval for a rare disease with no prior approved treatment.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Cognitive & Nootropic
- Best for
- Rett syndrome (the approved indication), IGF-1/BDNF signaling in neurodevelopmental research
Reported Side Effects
- Diarrhea (~80% of patients)
- Weight loss
- Vomiting
- Decreased appetite
- Upper respiratory tract infection
Warnings
- Monitor weight and nutritional status closely - weight loss is common
- Diarrhea may require dose interruption or reduction
- Hepatic monitoring recommended during treatment
- Long-term safety data beyond 1 year is limited
Known or Plausible Interactions
- Other oral medications (diarrhea may reduce absorption of co-administered drugs)
- CYP enzyme interactions are minimal due to renal elimination
Regulatory Context
FDA-approved (March 2023) for treatment of Rett syndrome in adults and pediatric patients 2 years of age and older. Available by prescription only. Marketed as Daybue by Acadia Pharmaceuticals. Orphan drug designation.
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | Rett Syndrome Symptom Improvement (Level A), Gastrointestinal Effects (Level A), and Communication and Behavior (Level B) |
| Primary citation count | 3 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Trofinetide Side Effects: Safety Signals and Warnings." Last reviewed 2026-04-04. https://examinepeptides.com/answers/trofinetide-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.